Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment
Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment
复制标题
DOI：
10.1093/jac/dkg244
复制
发表时间：
2003-06-01
影响因子：
5.2
通讯作者：
Mouton, Y
中科院分区：
文献类型：
--
作者：
Bahr, GM;De La Tribonnière, X;Mouton, Y
为了评估非特异性免疫疗法在恢复整体免疫力方面的潜力，我们在慢性感染HIV-1患者中检查了免疫调节剂Murabutide给药6周的临床耐受性和生物学效应。42例受试者在长期高效抗逆转录病毒治疗（HAART）后表现出免疫重建弱和病毒抑制无效，随机接受或不接受Murabutide 7 mg/天，连续5天/周。在免疫治疗期前后监测临床和免疫学参数。尽管观察到一些III级不良事件（治疗停止后可逆），但Murabutide给药通常耐受良好。有趣的是，与入选前水平相比，在免疫治疗周期后1周，只有接受莫拉布特治疗的患者的CD 4细胞、血小板计数和病毒载量检测不到的患者百分比显著增加（
In an effort to evaluate the potential of non-specific immunotherapy in restoring global immunity, we have examined the clinical tolerance and biological effects of a 6 week administration of the immunomodulator, murabutide, in chronically infected HIV-1 patients. Forty-two subjects, presenting weak immune reconstitution and ineffective virus suppression following long-term highly active antiretroviral therapy (HAART), were randomized to receive, or not, murabutide 7 mg/day on five consecutive days/week. Clinical and immunological parameters were monitored before and after the immunotherapy period. Administration of murabutide was generally well tolerated, although some grade III adverse events, reversible on treatment cessation, were observed. Interestingly, in comparison with pre-inclusion levels, at 1 week after the immunotherapy cycle, only murabutide recipients presented a significant increase in CD4 cells, platelet counts, and in the percentage of patients with undetectable viral loads (